- Home
- NLSP vs NERV Comparison
NLSP vs NERV Comparison
Compare NLSP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- NERV
- Stock Information
- Founded
- NLSP 2015
- NERV 2007
- Country
- NLSP Switzerland
- NERV United States
- Employees
- NLSP N/A
- NERV N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- NERV Health Care
- Exchange
- NLSP Nasdaq
- NERV Nasdaq
- Market Cap
- NLSP 12.4M
- NERV 12.0M
- IPO Year
- NLSP 2021
- NERV 2014
- Fundamental
- Price
- NLSP $2.07
- NERV $2.31
- Analyst Decision
- NLSP
- NERV Hold
- Analyst Count
- NLSP 0
- NERV 1
- Target Price
- NLSP N/A
- NERV $5.00
- AVG Volume (30 Days)
- NLSP 179.9K
- NERV 41.1K
- Earning Date
- NLSP 10-17-2025
- NERV 08-14-2025
- Dividend Yield
- NLSP N/A
- NERV N/A
- EPS Growth
- NLSP N/A
- NERV N/A
- EPS
- NLSP N/A
- NERV 1.48
- Revenue
- NLSP N/A
- NERV N/A
- Revenue This Year
- NLSP N/A
- NERV N/A
- Revenue Next Year
- NLSP N/A
- NERV N/A
- P/E Ratio
- NLSP N/A
- NERV $1.59
- Revenue Growth
- NLSP N/A
- NERV N/A
- 52 Week Low
- NLSP $1.30
- NERV $1.15
- 52 Week High
- NLSP $6.97
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- NLSP 42.25
- NERV 57.24
- Support Level
- NLSP $2.03
- NERV $2.31
- Resistance Level
- NLSP $2.29
- NERV $2.47
- Average True Range (ATR)
- NLSP 0.18
- NERV 0.17
- MACD
- NLSP -0.06
- NERV 0.01
- Stochastic Oscillator
- NLSP 3.88
- NERV 60.12
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.